“One Tough Mother” Creates Memorable Legacy

It’s not every day that someone decides to give away $100 million. On July 28, 2014, the OHSU Foundation announced that an anonymous donor was giving $100 million to the Knight Cancer Challenge, an unprecedented $1 billion initiative launched last September when Phil and Penny Knight announced that if OHSU could raise $500 million for cancer research in two years that they would donate an equal amount.

The $100 million gift – the largest private donation to the campaign to date – put the fundraising total over the $400 million mark in record time. After considerable speculation in media reports and an eventual release of confidentiality by the donor in late August, OHSU used a humorous video shared first on Facebook to signal that Gert Boyle was involved. The video featured the longtime chairman of Columbia Sportswear, made famous by the firm’s “one tough mother” ad campaign, chatting with OHSU Knight Cancer Institute Director Brian Druker, M.D., over lemonade about the $100 million anonymous gift. With the video’s release, Boyle agreed to speak with news reporters and confirm she was the donor.

In sharing the news of Boyle’s gift, OHSUF President Keith Todd said, “This gesture, and the motivation behind it, should (continued on page 11)
It is hard to believe it was a little more than a year ago that Nike Co-founder and Chairman Phil Knight and his wife, Penny, issued their surprise all-or-nothing pledge to donate $500 million to OHSU if we can raise an equal amount in two years.

I am inspired by the people who have supported us, from the children raising money at a lemonade stand to the politicians who’ve battled cancer and want Oregon to be the place where we end it, to “one tough mother” who is creating such a great legacy by inspiring us all to do what we can to help. I do not see these gifts as donations, but as investments that come with a responsibility to ensure that we once again change the way the world approaches cancer.

At the OHSU Knight Cancer Institute, we didn’t set out to just improve cancer treatment, we wanted to transform it. We pioneered a targeted approach that shuts down cancer cells without harming normal cells, offering a less toxic alternative to chemotherapy. Today, because of that work, there are more than 50 targeted treatments that are FDA-approved and hundreds more in clinical trials with the potential to save countless lives. Now it’s time to make the next leap forward. We are applying what we’ve learned about targeted therapy to chart a course to revolutionize early cancer detection. We recognize that the future lies in using the knowledge of what drives the growth of cancer to develop better ways to detect the disease in its genetic infancy, when it’s most treatable. In our view, this is the largest unmet need in cancer care today.

Because of your generosity and partnership, we are well on our way. We are already planning our buildings and recruiting spectacular scientists. Our strategy is to take a highly focused approach. The scientists we recruit to join our team will be equipped to work in collaboration with each other across disciplines to accelerate results. We will explore ways to improve imaging technologies that will search for subtle changes in tissue that signal cancer. And, we will develop simple non-invasive tests that uncover early signs of lethal forms of the disease. Our work will benefit those facing a first-time cancer diagnosis, as well as those who face possible recurrence.

Thank you for your support and partnership in helping create a world where all cancer patients win their battle.

Brian Druker, M.D.
Director, OHSU Knight Cancer Institute
JELD-WEN Chair for Leukemia Research
Associate Dean for Oncology

Enterprising second grader Michael Gray raised $610 for the Knight Cancer Challenge in two weeks as part of his class project. Michael then visited Dr. Druker’s lab.
The CLSB will also house the OHSU Center for Spatial Systems Biomedicine (OCSSB), a multi-disciplinary center established by the OHSU Knight Cancer Institute and other collaborators within the OHSU School of Medicine, to use advanced measurement and computing technologies to reveal the functions of the molecular machines that comprise living systems. Joe Gray, Ph.D., Gordon Moore Chair in the Department of Biomedical Engineering in the OHSU School of Medicine and associate director for translational research at the Knight Cancer Institute, directs the center. This new facility will also provide capacity to increase class sizes for OHSU’s medical, nursing and physician assistant programs, as well as the OSU/OHSU pharmacy program – all of which will help mitigate the state’s health care professionals workforce shortage.

The CLSB was funded by a unique public-private partnership model, including $110 million in state bonds, $92 million in OHSU institutional funding, $83 million in OHSU philanthropy (including a $40 million anonymous gift to OHSU, and $10 million from Bonnie and Gene Skourtes, D.M.D.) and $10 million from TriMet.

Collaborative Life Sciences Building Launches New Opportunities

A new building located on OHSU’s Schnitzer Campus at Portland’s South Waterfront will continue the first-of-its-kind partnership between OHSU, Oregon State University and Portland State University by expanding teaching facilities, class sizes and research activities. By sharing the $295 million state-of-the-art building, which opened this summer, OHSU will effectively grow its health and science programs without duplicating education and research space – an inspired use of limited state resources.

“At OHSU what we’ve found is that when we are open to the power of partnership, and willing to work with others to solve problems in the name of the public good, the opportunities are boundless. The Collaborative Life Sciences Building (CLSB) takes collaboration to the next level,” said OHSU President Joe Robertson, M.D., M.B.A.

Rather than divide the 650,000-square-foot building among the universities by floor, the building features integrated labs and shared classrooms throughout. Every aspect is designed to encourage interaction among faculty, graduates and undergraduates. Shared lab and office space promote frequent idea sharing, and simulation centers allow health care providers, students and staff across all health care professions to train side by side.

The CLSB will also house the OHSU Center for Spatial Systems Biomedicine (OCSSB), a multi-disciplinary center established by the OHSU Knight Cancer Institute and other collaborators within the OHSU School of Medicine, to use advanced measurement and computing technologies to reveal the functions of the molecular machines that comprise living systems. Joe Gray, Ph.D., Gordon Moore Chair in the Department of Biomedical Engineering in the OHSU School of Medicine and associate director for translational research at the Knight Cancer Institute, directs the center. This new facility will also provide capacity to increase class sizes for OHSU’s medical, nursing and physician assistant programs, as well as the OSU/OHSU pharmacy program – all of which will help mitigate the state’s health care professionals workforce shortage.

This new facility will also provide capacity to increase class sizes for OHSU’s medical, nursing and physician assistant programs, as well as the OSU/OHSU pharmacy program – all of which will help mitigate the state’s health care professionals workforce shortage.

The CLSB was funded by a unique public-private partnership model, including $110 million in state bonds, $92 million in OHSU institutional funding, $83 million in OHSU philanthropy (including a $40 million anonymous gift to OHSU, and $10 million from Bonnie and Gene Skourtes, D.M.D.) and $10 million from TriMet.
Transforming Breast Cancer Prevention and Care

Earlier this summer, Pepper Schedin, Ph.D., an internationally recognized scientist for her work in young women’s breast cancer, joined OHSU’s premier breast cancer team.

“For more than a decade, I have admired Dr. Schedin’s innovative work at the University of Colorado at Denver and was excited to recruit her to join our team,” said Lisa Coussens, Ph.D., associate director of basic research for the OHSU Knight Cancer Institute and chair of OHSU’s Department of Cell, Development and Cancer Biology. “Schedin’s research creates opportunities to change the way we think about women’s cancer – how and when it begins, what adds to a woman’s risks, and what we can do to intervene.”

Because breast cancer appears in many forms and has many potential causes, predicting a woman’s individual risk can be challenging. But there is at least one easily identifiable patient population facing a predictable risk: pregnant women. Schedin’s acclaimed program is devoted to the development of detection methods and post-natal therapies that protect women from these risk factors. The powerful premise behind Schedin’s work is that a woman’s body undergoes dramatic changes during key milestones of her reproductive life cycle (e.g., puberty, pregnancy, lactation and menopause). The body remodels tissues and organs to accommodate conception, childbearing, delivery and lactation in a process that reverses itself after pregnancy. By seeking out molecular markers of developing tumors through imaging and genomics, her team is working to develop detection and treatment methods that prevent the conditions that give rise to cancer.

Schedin, who continues to work closely with colleagues at the University of Colorado, says that while she was reluctant to leave the program and community she had established in Colorado, she was inspired to come to the OHSU Knight Cancer Institute because of Brian Druker, M.D.’s leadership, the opportunities to collaborate with Coussens and Joe Gray, Ph.D., and the resources, which she feels will enable her to achieve her research objectives more quickly than at any other institute in the world.

Schedin is already exploring novel collaborative projects with colleagues who can take her work in exciting new directions through the OHSU Center for Spatial Systems Biomedicine, the OHSU Center for Women’s Health and other exceptional programs.

Schedin received her bachelor’s degree in molecular, cellular and developmental biology and her Ph.D. in molecular genetics from the University of Colorado at Boulder. She has been published in numerous scientific journals and is frequently invited to speak at scientific gatherings around the world.
Lisa M. Coussens, Ph.D., associate director of basic research for the OHSU Knight Cancer Institute, was chosen to serve as a principal investigator on an international pancreatic cancer dream team funded by Stand Up To Cancer (SU2C) and The Lustgarten Foundation. The team will receive $8 million in funding over three years to explore how immune cells enable tumors to survive and grow – and ultimately develop treatments that exploit a patient’s own immune cells to eradicate their cancer.

As part of the project, Coussens, who is also chair of the Department of Cell, Developmental and Cancer Biology in the OHSU School of Medicine, will oversee a group of Knight Cancer Institute contributors. These researchers, among other things, will use bioinformatics to analyze tumor tissue from all of the patients participating in the projects’ clinical trials. This analysis will provide a detailed profile of how each patient’s tumor responds to one of five experimental treatments included in the study. In addition, the team will explore how the immune cells implicated in pancreatic cancer also might play a role in pancreatitis.

“Being part of this international Dream Team will build significant momentum for our exploration of the role of immune cells in enabling tumors to survive and grow,” Coussens said. “The consortium expands what we can do logarithmically.”

The SU2C Dream Team grant will build upon work under way by top OHSU pancreatic surgeons and Knight Cancer Institute scientists who are collaborating through OHSU’s Brenden-Colson Center for Pancreatic Care to develop treatment methods for pancreatic cancer while also exploring the source of pancreatic diseases at the molecular level. The center was formed in 2013 with a $25 million gift from a philanthropic partnership between Norman and Linda Brenden and the Colson Family Foundation.

SU2C has awarded grants to 12 Dream Teams and two Translational Cancer Research Grants. Including Coussens, the Knight Cancer Institute has three top scientists involved in these world-class, multi-institutional projects. Joe W. Gray, Ph.D., associate director for translational research at the institute, co-leads a breast cancer Dream Team focused on research for less toxic treatments for breast cancer. Tomasz Beer, M.D., deputy director of the institute, is one of six top scientists involved in a research Dream Team to study treatments for advanced prostate cancer.

Program to Support Cancer-Related Needs Statewide

The Knight Cancer Institute this fall launched a program to aid communities statewide in better understanding and addressing their cancer-related needs. The institute has committed to invest $1 million annually through this program to assist groups seeking to reduce the cancer burden in their communities.

Three tiers of grants are available to support a wide variety of projects that could range from conducting a needs assessment exploring a community’s cancer-related concerns to developing and implementing a program that addresses those concerns. The grants will fund community-identified projects anywhere along the cancer continuum from prevention to early detection and treatment through survivorship.

The Community Partnership Program will differ from many other community grants programs in that the multiple tiers of funding offer a method for organizations to take an initial idea and move through the funding tiers to develop a robust, sustainable program. Projects will be paired with an academic collaborator who will share best-practices, support program development and aid in evaluation measures. The mutual sharing of information between organizations and academic collaborators will help strengthen the Knight Cancer Institute’s understanding of Oregonians’ needs as they relate to the problem of cancer.
Stories of Giving

United We Stand – Against Cancer

Support for the Knight Cancer Challenge is coming from across the nation, but it’s especially strong here in Oregon. Earlier this summer Oregon businesses and labor groups came together to launch Unite for the Knight to raise money for the Knight Cancer Challenge.

Unite for the Knight includes the Oregon AFL-CIO, AFSCME, Associated Oregon Industries, Oregon Business Association, Oregon Business Council, Oregon State Building and Construction Trades Council and Portland Business Alliance. The goal is 100 percent participation of members represented by the coalition to help meet the $500 million Knight Cancer Challenge match and help OHSU end cancer as we know it.

Grateful Family Endows Research Fund

The Zmrhal family has had their share of cancer, with three family members affected by the disease. All three are cancer survivors and enjoying a full life. Randy and Linda Zmrhal and their children decided to make an investment to advance research at the Knight Cancer Institute. The Randy and Linda Zmrhal Endowment for Cancer Research will fund research that will improve the detection and treatment of cancer with a priority for lymphoma, melanoma, renal cell carcinoma and endometrial cancer – the cancers affecting their family. Randy, who was treated for lymphoma at the OHSU Oncology Center, especially wanted to recognize his oncologist, Gary Takahashi, M.D., F.A.C.P., and the staff for the care they provided.

“Our family was moved by Phil and Penny Knight’s generosity and interest in OHSU. The Knight Challenge motivated us to establish our endowment. We wanted to participate in providing funding for physicians and researchers to evolve leading-edge thinking in cancer research. We are really fortunate to have such a leading-edge cancer research institute in Oregon,” Randy said.
Homegrown Brands Do Their Part

It should come as no surprise that the company co-founded by Phil Knight would become an active supporter of the Knight Cancer Challenge. In February, Nike employees launched the Nike Meet Cancer Supper Club, a simple fundraising drive that is uniting the global Nike community from Beaverton to Brazil.

Intel Corporation, which has long collaborated with OHSU on research and healthcare technology advances, will highlight the KCC as part of its community giving campaign this fall and has pledged to donate nearly $2 million worth of equipment, technology and personnel services.

At Hoffman Construction Company, Wayne Drinkward, president, challenged employee-shareholders to raise $250,000 for OHSU’s effort, to be matched by the company. Drinkward personally promised $500,000 to match employee giving. Collectively, the Hoffman team exceeded their target, donating a total of $1,446,328.

Inspired by Hoffman Construction’s successful effort, Willamette Dental Group launched its own employee giving campaign in the fall. The campaign’s goal is to raise $250,000 in contributions from employees, matched by $250,000 from Willamette Dental Group and further matched by $500,000 from company founder Eugene Skourtes, D.M.D., and his wife Bonnie. The Skourtes are long-time supporters of the OHSU School of Dentistry.

The Standard has dedicated its annual employee giving campaign to the Challenge and has pledged to match employee donations two to one.

PGE Foundation, the corporate foundation of Portland General Electric, announced a $100,000 grant in support of the Challenge. “Cancer has affected the lives of so many – myself included,” said Gwyneth Gamble Booth, PGE Foundation chair. “This gift in support of ending cancer as we know it is a great way to carry out our mission of helping change the lives of so many in our community. We’re proud to stand in unity with the other businesses, unions and individuals lending their support.”

Grants Pass-based Dutch Bros. Coffee’s leaders decided to combine October’s national breast cancer awareness campaign with a special fundraising effort. Dutch Bros. is donating $5 for every “Be Aware” travel mug sold to support breast cancer research and the Challenge.

To see the growing list of corporate supporters see page 11 and keep checking the www.onedown.org blog.

Dollars to Doughnuts, These Kids Are with Us

Every penny counts in our fight against cancer – and a recent gift from students at Portland’s West Hills Montessori School came in the form of dollar bills, rolled quarters, and loose change in a shoebox.

Five third-grade students raised $869 for the Knight Cancer Challenge one chilly morning in January by selling over 10 dozen doughnuts, coffee and lots of hot chocolate. Genna Bialobok rallied her friends to raise support for the challenge to honor the memory of her friend who died at the age of six from cancer. The girls visited OHSU to present their shoebox of money and donned lab coats to tour Dr. Brian Druker’s laboratory, where they asked many questions, tried their hand at pipetting and looked at cells under a microscope.
Legacy Gifts Benefit Challenge

The OHSU Knight Cancer Institute is profoundly grateful for the support provided by donors who make planned gifts, such as designating a gift in their will, to benefit the Institute. Through their generosity, these donors create meaningful legacies for future generations and provide funding for the innovative research of the future.

Inspired by the work of Brian Druker, M.D., longtime Portland resident and native Oregonian Fran Matson is establishing a leadership legacy gift through her estate plans to benefit the Knight Cancer Institute. All gifts to cancer care and research programs, including documented planned gifts, count toward the Challenge. Of her gift, Matson said, “It is the best investment that can be made in my opinion. Good health is the most important thing there is, and ending this hideous disease is critical.”

For more information about bequests and other planned gifts, please contact Mike Macnab at 503 552-0702 or macnab@ohsu.edu.

OCF Gives Largest-Ever Discretionary Grant

When Phil Knight and his wife, Penny, challenged Oregonians and the rest of the country to take a bold stand against cancer, the Oregon Community Foundation (OCF) boldly answered with a $1 million grant. The award, announced by the OCF board just two months after the Knights made their pledge, represents the largest discretionary grant in OCF’s 40-year history.

“The Oregon Community Foundation’s board of directors is excited to support and recognize the challenge posed by Phil and Penny Knight in the fight to cure cancer,” said Max Williams, president and chief executive officer of OCF. “We are confident that philanthropists not only from Oregon, but from across the country, will rise to the challenge. The results of this effort will dramatically affect cancer research around the world.”

Many OCF donors have been generous in their individual support of the OHSU Foundation over the years. “This grant signals our intention to honor those gifts by increasing their impact,” said Williams.

Rose Festival Joins the Challenge

There were floats and flowers aplenty at the 2014 Portland Rose Festival Parade, but what made this year special was an army of fundraising foot soldiers. The Rose Festival used its popular public events to bring awareness to, encourage community support of and directly raise funds for the Knight Cancer Challenge. Volunteers from U.S. Bank and OHSU worked the crowds to collect donations by the bucket for the Knight Cancer Challenge – the first exclusive charity in the festival’s 107 years.

“The Rose Festival offers an extraordinary platform every year for dozens of nonprofits to raise awareness of their organizations and benefit their missions through our parades and sanctioned events,” said Todd Johnston, president of the Portland Rose Festival Foundation. “We’re both pleased and proud to be part of one of the most unprecedented charitable appeals of all time, the Knight Cancer Challenge.”

From left: Brian Druker, M.D., with OCF President Max Williams and OCF Board Chair Sue Miller

OHSU volunteers join in the Rose Festival Parade fun.
Research Updates

Award Advances Imaging for Cancer Treatment

When doctors treat breast cancer patients with the latest targeted cancer drugs, many patients initially see an improvement but later relapse and develop a resistance to treatment. OHSU researchers believe that by developing better imaging technologies they will be able to see how molecules change and rearrange themselves in response to cancer treatment, ultimately allowing them to create more effective treatments with a lasting response.

Summer L. Gibbs, Ph.D., and Xiaolin Nan, Ph.D., both assistant professors in OHSU’s Department of Biomedical Engineering and the Center for Spatial Systems Biomedicine, recently received a prestigious Damon Runyon-Rachleff Innovation Award to pursue this exceptionally creative line of work. They will receive $450,000 over three years to develop an advanced high-resolution microscopy instrument that allows them to zoom in to see what’s happening at the molecular level in greater spatial and spectral detail. Specifically, they are looking at the HER2 signaling pathway in breast cancer cells and its response to drugs such as lapatinib. They anticipate the findings of this work will significantly improve our understanding of the spatial and temporal organization of cancer cell signaling, enabling development of more effective targeted cancer therapeutics with lasting response. Gibbs and Nan have also received funding from the M.J. Murdock Charitable Trust and FEI Inc. to support this line of research.

ACS Grant Funds Research to Study Immune System’s Role in Cancer

Through a rigorous application process, Terry R. Medler, Ph.D., received a $163,500 grant from the American Cancer Society to study how the immune system can malfunction and foster growth of cancer cells. The grant will fund the study of how a protein fragment, called complement C5a, contributes to squamous carcinogenesis. Medler’s work will explore how upon encountering pathogens, or damaged cells, this protein becomes activated, binds to C5a receptors on immune cells and initiates inflammation. The inflammation is initially aimed at eliminating the pathogen, or damaged cell, but then goes into overdrive.

The award will contribute to OHSU’s Knight Cancer Challenge. “Our amazing volunteers and donors saw the enormous potential to fund a bright young researcher, Dr. Medler, adding to our distinguished list of research grantees – which includes local researcher Dr. Brian Druker – and allowed us to partner with OHSU on the Knight Cancer Challenge,” said Ryan Price, American Cancer Society community engagement senior director. The grant is funded in part by proceeds donated to the ACS’s Hope Ball, which took place earlier in 2014.

FDA Expands Use of Prostate Cancer Pill

In September, the FDA expanded the approval for a prostate cancer drug, enzalutamide, based on studies led by OHSU Knight Cancer Institute showing the drug prolongs life in patients who haven’t yet received chemotherapy. The FDA had previously approved the drug for patients with more advanced prostate cancer. The latest approval allows patients to delay receiving chemotherapy, which can have debilitating side effects.

Tomasz Beer, M.D., deputy director of the OHSU Knight Cancer Institute and co-principal investigator of the study, says the average delay is approximately 17 months. According to trial results the drug also reduces the risk of death by 30 percent. The study was conducted on more than 1,700 patients in numerous countries.

“In the past few years we have vastly expanded treatment options for prostate cancer,” Beer said. “We are working hard to provide answers and options for men whose disease still resists treatment.”

Beer’s team of prostate cancer researchers at the institute has been involved in, or led, clinical trials for four of the five new treatments developed for prostate cancer in recent years.
Awards and Honors

Joshi Alumkal, M.D., co-director of the Prostate Cancer Program, will receive the 2014 Richard T. Jones New Investigator Award from the OHSU Medical Research Foundation. This award recognizes a new investigator who shows exceptional promise early in a career in biomedical research.

Grover Bagby Jr., M.D., founding director of the OHSU Knight Cancer Institute, will receive the 2014 Mentor Award from the American Society of Hematology in December for sustained, outstanding commitment to the training and career development of early-career hematologists. His mentees cite his selfless leadership and caring dedication to the development of scientific expertise and tradition as critical elements of his success in influencing the lives of his more than 40 former trainees, who now serve as successful clinicians, researchers, policy makers, and administrators. Bagby is a professor in OHSU’s Department of Molecular and Medical Genetics.

Joe Gray, Ph.D., was named the 18th recipient of the Alfred G. Knudson Award in Cancer Genetics from NIH’s National Cancer Institute for his outstanding contributions to the field of cancer genetics. Gray holds multiple positions at OHSU, including as associate director for translational research for the OHSU Knight Cancer Institute.

Jeffrey Tyner, Ph.D., a leukemia researcher for the OHSU Knight Cancer Institute, is one of two recipients of the second annual Martin and Rose Wachtel Cancer Research Award from the American Association for the Advancement of Science (AAAS). He received the award for research that simultaneously identifies cancer-causing mutations and drugs that target these mutations. Tyner’s award essay was published in Science Translational Medicine.

The OHSU Center for Women’s Health Circle of Giving, a group of philanthropists who pool and target their resources to advance women’s health research at OHSU, recently awarded two $125,000 grants to OHSU cancer researchers. Stephen Chui, M.D., a breast cancer specialist and assistant professor in OHSU’s Division of Hematology and Medical Oncology, and Paul Spellman, Ph.D., a top Knight Cancer Institute researcher and professor in OHSU’s Department of Molecular and Medical Genetics, seek to develop a blood-based system to detect remaining cancer cells after therapy in triple-negative (and eventually all) breast cancers. They hope their new technique will help identify tiny amounts of cancer cells that are currently undetectable, and thus eventually enable treatment much earlier than is currently possible. Summer Gibbs, Ph.D., assistant professor of biomedical engineering, will also work on innovative research involving triple-negative breast cancer. Working with Lisa Coussens, Ph.D., she will use a novel high-resolution 20-color immunofluorescence imaging technology to better understand the complex immunologic makeup of breast cancer and thus help develop targeted treatment.

Each year, philanthropy makes it possible for the OHSU Knight Cancer Institute to provide clinical cancer research awards and career development awards to investigators early in their career. Receiving 2013-2014 Clinical Research Scholar Awards are Joshi Alumkal, M.D., made possible by Grace and Ken Evenstad and Eneida Nemecek, M.D., M.B.A., Christopher W. Ryan, M.D., Emma Scott, MBBCH, and Stephen E.F. Spurgeon, M.D., made possible by Eric and Janet Parsons. Recent career development award recipients are: Jacob Henderson, M.D., and Evan Lind, Ph.D., who each received an Umpqua Bank Innovation Award for Pediatric Cancer Research; Baotong Xie, Ph.D., and Terry Medler, Ph.D., who each received the Cathy and Jim Rudd Cancer Research Development Award; and Stephanie Krasnow, Ph.D., who received the U.S. Bank Cancer Research Development Award.
not be a surprise to Oregonians who know Gert and her personal story. For decades, she has served as a model of what can be achieved when you simply do not have the words ‘can’t’ or ‘impossible’ in your vocabulary. She and her family have been longtime supporters of OHSU’s Knight Cancer Institute. Her late sister, Hildegard Lamfrom, was a renowned scientist and a personal mentor to Knight Cancer Institute Director Dr. Brian Druker, whose vision to end cancer as we know it has gained the passionate support of thousands during this past year.”

“I can’t think of a better way to leave a legacy behind than to donate to Brian Druker,” said Boyle. Boyle said she hoped sharing her identity would inspire others to join her in supporting the Knight Cancer Challenge.

To view the video featuring Boyle and Druker, as well as see other news about the campaign, visit www.onedown.org.

How to Donate

**Call Us: 800 462-6608 or 503 228-1730**
We’ll tell you about all of the options.

**Email Us: supporttheknight@ohsu.edu**
We would love to answer your questions.

**Visit our website: onedown.org**
There you will find more information and a simple online donation form.

**Create a fundraising page**
Visit www.ohsu.edu/cancer and click on the How You Can Help “Get Involved” section.

**Send us a check**
Payable to OHSU Foundation (note Knight Cancer Challenge on memo line), Mail Stop 45, PO Box 4000, Portland, OR 97208

*Includes $200 million from State of Oregon

**HOW MUCH RAISED? More than $440 million**
of the $500 million needed by February 4, 2016, World Cancer Day, to activate an additional $500 million gift from Nike co-founder Phil Knight and his wife, Penny.

**HOW MANY DONORS? A lot.**
6,928+ donors to date from all 50 states, the District of Columbia and gifts from outside the United States

**WHERE FROM? All over.**
60 donors from Florida
54 donors from New York
32 donors from Minnesota
27 donors from Texas
9 donors from the United Kingdom
3 donors from Canada
2 donors from Taiwan, Republic of China

**HOW MANY $1 MILLION+ GIFTS?**
Thirty six.
6 Anonymous
20 from Oregon
4 from Washington
1 from California
1 from Michigan
1 from Minnesota
2 from New York
1 from Wyoming

**WHO SPONSORS THIS? Here are a few.**

American Cancer Society
Cambia Health Foundation
Dutch Bros. Coffee
FEI
Hoffman Construction Company
Hyundai Hope on Wheels
Intel Corporation
JE Dunn Construction
Kay Yow Cancer Fund
Kuni Automotive
Newman’s Own Foundation
Nike
NW Natural
Oregon Community Foundation
PGE
Parr Lumber
Portland Winterhawks
Reser Family Foundation
Safeway Foundation
Sherie Hildreth Ovarian Cancer Foundation
The Ford Family Foundation
The Leukemia & Lymphoma Society
The Standard
United Way
Wieden + Kennedy
Willamette Dental Group
ZGF Architects
CANCER WOULDN'T PLAY NICE, SO THESE GIRLS TOOK A STAND.

Thousands of children and adults are raising money to help Dr. Brian Druker and his OHSU Knight Cancer Institute team go after cancer as aggressively as it comes after us.

Are you ready to join us? Visit onedown.org

WE’RE PUTTING THE SQUEEZE ON CANCER.